Waystar (WAY) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition accelerates AI-powered transformation, targeting friction points in the healthcare revenue cycle and expanding the platform’s reach and capabilities, including clinical intelligence and automation.

• Expands total addressable market by over 15% and deepens relationships with more than 1,000 hospitals, health systems, and premier providers.

• Integrates proprietary AI models and clinical data, empowering over one million providers to prevent denials, reduce manual work, and improve financial performance.

• Enhances innovation, market leadership, and the ability to deliver ROI to clients and shareholders.

• Combined company expected to serve 17 of the 20 U.S. News Best Hospitals.

Financial terms and conditions

• Purchase price is $1.25 billion, funded 50% in cash and 50% in common stock; total enterprise value represents a high teens EV/2025E PF synergized Adj. EBITDA multiple.

• Iodine shareholders will own about 8% of the combined entity; current shareholders will own 92%.

• Advent, Iodine’s largest shareholder, will receive all consideration in stock, nominate a director to the board, and agree to an 18-month lock-up.

• Select large shareholders subject to 18-month lock-up; others to at least 6-month transfer restriction.

• Adjusted net leverage ratio at close expected to be approximately 3.5x, with continued deleveraging anticipated.

Synergies and expected cost savings

• Over $15 million in run-rate cost synergies anticipated within 18–24 months post-close, driven by integration efficiencies and cross-sell opportunities.

• Significant cross-sell potential between client bases and platforms, leveraging a subscription-based revenue model.

• Immediate accretion to gross margin and adjusted EBITDA; accretive to revenue growth and non-GAAP net income per share by 2027.

• 100%+ identified synergies achieved in nine prior acquisitions.

• Operational synergies expected with speed and efficiency.